GeoVax Labs, Inc., a biotechnology firm specializing in vaccine development, has recently been issued U.S. Patent No. 12,329,808 for a groundbreaking vaccine construct designed to prevent malaria. This patent underscores the company’s innovative approach to combating infectious diseases through its multi-antigenic vaccine platform. The patented technology involves a recombinant Modified Vaccinia Ankara (MVA) viral vector that expresses immunogenic proteins from Plasmodium falciparum, the parasite responsible for malaria. This design facilitates the in vivo assembly of virus-like particles (VLPs), enhancing the vaccine’s potency by inducing both humoral and T-cell responses.
David Dodd, President and CEO of GeoVax, emphasized the importance of this patent in advancing vaccines for high-consequence pathogens, highlighting the company’s commitment to global health security. With malaria causing over 600,000 deaths annually, primarily in sub-Saharan Africa, the development of an effective vaccine is crucial. GeoVax’s MVA-based platform offers a promising solution by potentially providing durable immunity against malaria and other emerging pathogens.
This patent adds to GeoVax’s extensive intellectual property portfolio, which includes over 135 granted or pending patent applications across various fields such as oncology, infectious diseases, and biodefense. The company’s strategic focus on developing vaccines and therapies for unmet medical needs is further solidified by this achievement. GeoVax’s ongoing clinical programs, including a next-generation COVID-19 vaccine and an oncolytic cancer therapy, demonstrate its broad commitment to addressing significant health challenges.
The issuance of this patent not only represents a milestone for GeoVax but also contributes to the global effort to eradicate malaria, a disease that continues to pose a severe threat to public health worldwide. The company’s innovative vaccine construct could play a pivotal role in reducing the burden of malaria, especially in regions most affected by the disease.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp
. The source URL for this press release is GeoVax Secures Patent for Innovative Malaria Vaccine Design.